Clinical performance of serum prostate‐specific antigen isoform [‐2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project

To test the sensitivity, specificity and accuracy of serum prostate‐specific antigen isoform [‐2]proPSA (p2PSA), %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer (PCa) undergoing prostate biopsy for suspected PCa. To evaluate the potential reduction in unnecessary biopsies and the characteristics of potentially missed cases of PCa that would result from using serum p2PSA, %p2PSA and PHI.

[1]  F. Montorsi,et al.  Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. , 2012, The Journal of urology.

[2]  D Andrew Loblaw,et al.  Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Moyer.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[4]  T. McNicholas,et al.  Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66. , 2012, European urology.

[5]  F. Montorsi,et al.  Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. , 2012, European urology.

[6]  Jingchun Luo,et al.  Early onset prostate cancer has a significant genetic component , 2012, The Prostate.

[7]  F. Montorsi,et al.  Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. , 2011, European urology.

[8]  John T. Wei,et al.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.

[9]  A. Semjonow,et al.  Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. , 2010, Clinical biochemistry.

[10]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[11]  A. Godwin,et al.  Prostate cancer risk assessment program: a 10-year update of cancer detection. , 2007, The Journal of urology.

[12]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[14]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[15]  P. Engstrom,et al.  Relative risk of prostate cancer for men with affected relatives: Systematic review and meta‐analysis , 2003, International journal of cancer.

[16]  R. Houlston,et al.  A systematic review and meta‐analysis of familial prostate cancer risk , 2003, BJU international.

[17]  W. Catalona,et al.  Screening for prostate cancer in high risk populations. , 2002, The Journal of urology.

[18]  O. Bratt.  Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.

[19]  T. Tammela,et al.  Family history and prostate cancer screening with prostate-specific antigen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Olsson,et al.  Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. , 1999, European journal of cancer.

[21]  S. Narod,et al.  Family history and the risk of prostatic carcinoma in a high risk group of urological patients. , 1995, The Journal of urology.

[22]  S. Narod,et al.  The impact of family history on early detection of prostate cancer , 1995, Nature Medicine.

[23]  T. Beaty,et al.  Hereditary prostate cancer: epidemiologic and clinical features. , 1993, The Journal of urology.

[24]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[25]  伊関 亮.  Development of a nomogram for predicting a positive repeat prostate biopsy , 2014 .

[26]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.